Atlas Bio
Atlas Bio uses foundation models of human biology to conduct in silico clinical trials, helping biopharma teams validate drug development.
Atlas Bio is a biotech & life sciences company based in CH, founded in 2024. It has raised $12.5 million in disclosed funding. Its latest round was a Seed of $12.5 million in October 2026.
Overview
Founded in 2024, Atlas Bio develops a foundation AI model of human biology designed to conduct in silico clinical trials [0]. The platform assists biopharma organizations by simulating patient-level transcriptomic responses to treatments, allowing companies to evaluate development paths, differentiate assets, and select optimal indications before committing to expensive Phase II clinical trials [0]. Unlike traditional approaches that rely on historical data or trial outcomes, the company’s technology utilizes measured human transcriptomic data to predict drug effects without requiring prior asset-specific efficacy information [0]. Atlas Bio’s model enables developers to compare different mechanisms within the same patient profiles, helping to de-risk investment decisions and improve R&D efficiency [0]. Operating as a partner-driven model, Atlas Bio provides customized analysis for pharmaceutical and biotech teams under nondisclosure agreements [0]. The company has raised $12.5 million in seed funding to support its mission of enhancing clinical development standards [Registry].
Funding
Total disclosed: $12.5M across 1 round. Computed only from sourced rounds.
Investors
Questions and answers
What does Atlas Bio do?
Atlas Bio uses foundation models of human biology to conduct in silico clinical trials, helping biopharma teams validate drug development.
How much has Atlas Bio raised?
Atlas Bio has raised $12.5 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Atlas Bio?
Investors in Atlas Bio include Creandum, First Momentum Ventures, and LEA Partners.
When and where was Atlas Bio founded?
Atlas Bio was founded in 2024 and is based in CH.
Timeline
Founded
Sources
- 1.Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing — Tech.eu, Oct 27, 2026
- 2.Atlas Bio · Official